Updated hourlyHourly refreshMon, Oct 26, 2026
Press Release Database
Recent press releases, indexed by topic.
Finance · Biotech & pharma
New York, New York--(August 26, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the "Class Period"), of the important September 28, 2026 lead plaintiff deadline.SO WHAT: If you purchased Capricor securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a...
Aug 26 · 23:48·Newsfile
Finance · Biotech & pharma
SAN FRANCISCO, Aug. 26, 2026 -- National investor rights law firm Hagens Berman highlights developments surrounding Capricor Therapeutics, Inc. (NASDAQ: CAPR). Following Capricor's recent Q2 2026 earnings release and conference call—notable for an omission of management Q&A...
Aug 26 · 22:54·PR Newswire
Healthcare · Biotech & pharma
Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients
Aug 26 · 21:16·GlobeNewswire
Finance · Biotech & pharma
LOS ANGELES, Aug. 26, 2026 -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Sionna Therapeutics, Inc. (“Sionna” or the “Company”) (NASDAQ: SION) investors concerning the Company’s possible violations of the federal securities laws.
Aug 26 · 20:30·GlobeNewswire
Healthcare · Biotech & pharma
Toronto, Ontario--(August 26, 2026) - Vimy Pharmaceuticals Inc. ("Vimy Pharma" or the "Company") and Harmony Acquisitions Corp. (TSXV: MONY.P) ("Harmony") are pleased to jointly announce that, further to their press release dated August 6, 2026 announcing the entering into of a non-binding letter of intent to complete a business combination transaction which will constitute a reverse take-over of Harmony (the "Transaction"), Vimy Pharma has launched a "best efforts" brokered...
Aug 26 · 20:18·Newsfile
Finance · Healthcare
SAN DIEGO, Aug. 26, 2026 -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that members of its executive team are scheduled to participate in multiple upcoming investor conferences:
Aug 26 · 20:15·GlobeNewswire
Finance · Biotech & pharma
New York, New York--(August 26, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) on behalf of investors that purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26, 2026 (the "Class Period").CLICK HERE TO JOIN THE CASEIf you are an investor in Capricor and have suffered losses, you may CLICK HERE to contact us. You may also...
Aug 26 · 19:00·Newsfile
Healthcare · Biotech & pharma
This release contains multimedia assets available for download here
Aug 26 · 16:59·GlobeNewswire
Finance · Biotech & pharma
New York, New York--(August 26, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC).CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATIONIf you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us. You may also contact...
Aug 26 · 16:35·Newsfile
Finance · Healthcare
San Diego, California--(August 26, 2026) - Robbins LLP reminds investors that a securities class action has been filed on behalf of investors who purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between August 1, 2025 and May 15, 2026, inclusive (the "Class Period").The lawsuit alleges that Regeneron Pharmaceuticals misled investors regarding the viability and prospects of its Phase 3 Fianlimab-Libtayo clinical trial for patients with...
Aug 26 · 16:10·Newsfile
Biotech & pharma
DURHAM, N.C., Aug. 26, 2026 -- Priovant Therapeutics announced today the publication in JAMA Dermatology of skin-specific outcomes from the Phase 3 VALOR trial evaluating brepocitinib, a first-in-class oral TYK2 and JAK1 inhibitor, in adults with dermatomyositis (DM). Primary efficacy and safety results from the trial were previously published in the New England Journal of Medicine, including benefit on measures of skin disease, muscle strength, physical function, and steroid-sparing.
Aug 26 · 15:11·GlobeNewswire
Healthcare · Biotech & pharma
Moffitt Cancer Center's Dr. Lary Robinson discusses blood-based biomarkers in early lung cancer detection and ongoing CIZ1B clinical study WASHINGTON, Aug. 26, 2026 -- Cizzle Bio Inc., a biotechnology company advancing biomarker blood tests for early cancer detection, today...
Aug 26 · 15:00·PR Newswire